Keyphrases
Average Lifetime
10%
Baseline Analysis
10%
Canadian Dollar
10%
Canadian Healthcare
10%
Cohort Model
10%
Computational Imaging
10%
Conventional CT
10%
Cost Reduction
20%
Cost Savings
10%
Cost-effectiveness
10%
Curative Intent
30%
Decision-analytic Model
10%
Diagnostic Costs
10%
Diagnostic Features
10%
Diagnostic Probability
10%
Disease Course
10%
Dominant Strategy
10%
Follicular Lymphoma
100%
Incremental Cost-effectiveness Ratio
20%
Lifetime Cost
10%
Lymphoma Patients
20%
Net Monetary Benefit
10%
Non-curative
10%
PET-based
100%
Positron Emission Tomography-computed Tomography (PET-CT)
100%
Probabilistic Sensitivity Analysis
20%
Quality-adjusted Life Years
70%
Radiation Therapy
50%
Sensitivity Analysis
20%
State Transition
10%
Willingness-to-pay Threshold
10%
Medicine and Dentistry
Cost-Effectiveness Analysis
30%
Diagnosis
10%
Disease Course
10%
Follicular Lymphoma
100%
Health Care
10%
Health Care Cost
100%
Lifespan
10%
Polyethylene Terephthalate
100%
Population Research
10%
Positron Emission Tomography-Computed Tomography
100%
Quality Adjusted Life Year
70%
Radiation Therapy
50%
Pharmacology, Toxicology and Pharmaceutical Science
Disease Course
9%
Follicular Lymphoma
100%
Polyethylene Terephthalate
100%
Population Study
9%
Biochemistry, Genetics and Molecular Biology
Lifespan
10%
Population Research
10%
Positron Emission Tomography-Computed Tomography
100%
Quality Adjusted Life Year
70%
Agricultural and Biological Sciences
Canadians
18%
Health Service
9%
Polyethylene Terephthalate
100%